CTIS2022-501172-25-00招募中1 期
A Randomized, Double-blind, Parallel-group, Active Controlled Trial with Open-label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE) - M22-061
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Documented history of migraine (with or without aura) for >= 12 months prior to screening (Visit 1), History of >= 4 migraine days per month who require preventive treatment of migraine and are eligible for conventional migraine prophylaxis.
排除标准
- •Have used topiramate or atogepant in the past., Have clinically significant cardiovascular, cerebrovascular, hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
研究者
相似试验
未知
不适用
A randomized, double-blind, parallel-group, active-controlled, multi-center study to evaluate the long-term safety and efficacy of combination of solifenacin succinate with mirabegron compared to solifenacin succinate and mirabegron in subjects with overactive bladder-N31N31PER-046-14Astellas Pharma Europe B.V,
招募中
1 期
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosisPostmenopausal osteoporosisMedDRA version: 20.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2022-002312-23-BGShandong Boan Biotechnology Co., Ltd.524
招募中
1 期
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis.Postmenopausal osteoporosisMedDRA version: 20.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2022-002312-23-CZShandong Boan Biotechnology Co., Ltd.524
进行中（未招募）
不适用
study to compare the blood pressure lowering efficacy of aliskiren, a combination of aliskiren plus amlodipine, and ramipril in elderly patients with mild to moderate hypertension. It will also compare the long-term safety of an aliskiren-based regimen to a ramipril-based regimeEUCTR2013-001562-42-HUovartis Pharma Services AG1,392
进行中（未招募）
不适用
A randomized, double-blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus an amlodipinetreatment strategy in achieving blood pressure control in patients with stage 1 or stage 2 hypertension or uncontrolled on present monotherapy - NDMedDRA version: 6.1Level: PTClassification code 10015488Essential hypertensionEUCTR2005-000684-26-ITOVARTIS FARMA1,244